Credit: Gan & Lee Pharmaceuticals website
July 22, 2024 10:53 AM EDT
R&D

Chi­nese biotech boasts com­pet­i­tive Phase 2b weight loss da­ta for GLP-1 drug

Max Bayer

Pharma Reporter

Fresh off Eli Lil­ly’s tirzepatide ap­proval for weight loss in Chi­na, Bei­jing-based Gan & Lee Phar­ma­ceu­ti­cals post­ed Phase 2b da­ta of its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times